Duke logo

Macrogenics: Margetuximab for HER2 Gastric Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the study drugs are safe for patients, if they can reduce or slow the growth of your cancer, and what effects, good or bad, these drugs may have on your body.

What is the Condition Being Studied?

Gastric Cancer

Who Can Participate in the Study?

Adults who:
- Have unresectable HER2 positive gastric cancer

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Receive both margetuximab and pembrolizumab given once every 3 weeks
-- Both pembrolizumab and margetuximab will be given by injection into your vein in the clinic at Duke

Study Details

Full Title
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00068590
NCT:NCT02689284
Phase
Phase I/II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698